109 related articles for article (PubMed ID: 29464092)
1. mTOR inhibition enhances efficacy of dasatinib in
Gotesman M; Vo TT; Herzog LO; Tea T; Mallya S; Tasian SK; Konopleva M; Fruman DA
Oncotarget; 2018 Jan; 9(5):6562-6571. PubMed ID: 29464092
[TBL] [Abstract][Full Text] [Related]
2. Rapid molecular response to dasatinib in Ph-like acute lymphoblastic leukemia patients with ABL1 rearrangements: case series and literature review.
Tan KW; Zhu YY; Qiu QC; Wang M; Shen HJ; Huang SM; Cao HY; Wan CL; Li YY; Dai HP; Xue SL
Ann Hematol; 2023 Sep; 102(9):2397-2402. PubMed ID: 37103615
[TBL] [Abstract][Full Text] [Related]
3. Novel pharmacological and dietary approaches to target mTOR in B-cell acute lymphoblastic leukemia.
Buono R; Alhaddad M; Fruman DA
Front Oncol; 2023; 13():1162694. PubMed ID: 37124486
[TBL] [Abstract][Full Text] [Related]
4. Targeting eIF4F translation complex sensitizes B-ALL cells to tyrosine kinase inhibition.
Vo TT; Herzog LO; Buono R; Lee JS; Mallya S; Duong MR; Thao J; Gotesman M; Fruman DA
Sci Rep; 2021 Nov; 11(1):21689. PubMed ID: 34737376
[TBL] [Abstract][Full Text] [Related]
5. Tyrosine kinase inhibitor use in pediatric Philadelphia chromosome-positive acute lymphoblastic anemia.
Hunger SP
Hematology Am Soc Hematol Educ Program; 2011; 2011():361-5. PubMed ID: 22160058
[TBL] [Abstract][Full Text] [Related]
6. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia.
Roberts KG; Li Y; Payne-Turner D; Harvey RC; Yang YL; Pei D; McCastlain K; Ding L; Lu C; Song G; Ma J; Becksfort J; Rusch M; Chen SC; Easton J; Cheng J; Boggs K; Santiago-Morales N; Iacobucci I; Fulton RS; Wen J; Valentine M; Cheng C; Paugh SW; Devidas M; Chen IM; Reshmi S; Smith A; Hedlund E; Gupta P; Nagahawatte P; Wu G; Chen X; Yergeau D; Vadodaria B; Mulder H; Winick NJ; Larsen EC; Carroll WL; Heerema NA; Carroll AJ; Grayson G; Tasian SK; Moore AS; Keller F; Frei-Jones M; Whitlock JA; Raetz EA; White DL; Hughes TP; Guidry Auvil JM; Smith MA; Marcucci G; Bloomfield CD; Mrózek K; Kohlschmidt J; Stock W; Kornblau SM; Konopleva M; Paietta E; Pui CH; Jeha S; Relling MV; Evans WE; Gerhard DS; Gastier-Foster JM; Mardis E; Wilson RK; Loh ML; Downing JR; Hunger SP; Willman CL; Zhang J; Mullighan CG
N Engl J Med; 2014 Sep; 371(11):1005-15. PubMed ID: 25207766
[TBL] [Abstract][Full Text] [Related]
7. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
8. Nutlin-3 plus tanshinone IIA exhibits synergetic anti-leukemia effect with imatinib by reactivating p53 and inhibiting the AKT/mTOR pathway in Ph+ ALL.
Guo Y; Li Y; Xiang B; Huang XO; Ma HB; Wang FF; Gong YP
Biochem J; 2017 Dec; 474(24):4153-4170. PubMed ID: 29046392
[TBL] [Abstract][Full Text] [Related]
9. Oncogenic role and therapeutic targeting of ABL-class and JAK-STAT activating kinase alterations in Ph-like ALL.
Roberts KG; Yang YL; Payne-Turner D; Lin W; Files JK; Dickerson K; Gu Z; Taunton J; Janke LJ; Chen T; Loh ML; Hunger SP; Mullighan CG
Blood Adv; 2017 Sep; 1(20):1657-1671. PubMed ID: 29296813
[TBL] [Abstract][Full Text] [Related]
10. PF-114, a potent and selective inhibitor of native and mutated BCR/ABL is active against Philadelphia chromosome-positive (Ph+) leukemias harboring the T315I mutation.
Mian AA; Rafiei A; Haberbosch I; Zeifman A; Titov I; Stroylov V; Metodieva A; Stroganov O; Novikov F; Brill B; Chilov G; Hoelzer D; Ottmann OG; Ruthardt M
Leukemia; 2015 May; 29(5):1104-14. PubMed ID: 25394714
[TBL] [Abstract][Full Text] [Related]
11. Targeting BCL-2 and ABL/LYN in Philadelphia chromosome-positive acute lymphoblastic leukemia.
Leonard JT; Rowley JS; Eide CA; Traer E; Hayes-Lattin B; Loriaux M; Spurgeon SE; Druker BJ; Tyner JW; Chang BH
Sci Transl Med; 2016 Aug; 8(354):354ra114. PubMed ID: 27582059
[TBL] [Abstract][Full Text] [Related]
12. Susceptibility of Ph-positive all to TKI therapy associated with Bcr-Abl rearrangement patterns: a retrospective analysis.
Jing Y; Chen H; Liu M; Zhou M; Guo Y; Gao C; Wang Q; Li H; Zhao Y; Bo J; Huang W; Zhu H; Zhang Y; Yu L
PLoS One; 2014; 9(11):e110431. PubMed ID: 25415187
[TBL] [Abstract][Full Text] [Related]
13. Philadelphia-Like Genetic Rearrangements in Adults With B-Cell ALL: Refractoriness to Chemotherapy and Response to Tyrosine Kinase Inhibitor in
Senapati J; Jabbour E; Konopleva M; Short NJ; Tang G; Daver N; Kebriaei P; Kadia T; Pemmaraju N; Takahashi K; DiNardo C; Sasaki K; Borthakur G; Thakral B; Kanagal-Shamanna R; Patel K; Ravandi F; Roberts K; Mullighan C; Kantarjian H; Jain N
JCO Precis Oncol; 2023 May; 7():e2200707. PubMed ID: 37196217
[TBL] [Abstract][Full Text] [Related]
14. Network Analysis Reveals Synergistic Genetic Dependencies for Rational Combination Therapy in Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia.
Ding YY; Kim H; Madden K; Loftus JP; Chen GM; Allen DH; Zhang R; Xu J; Chen CH; Hu Y; Tasian SK; Tan K
Clin Cancer Res; 2021 Sep; 27(18):5109-5122. PubMed ID: 34210682
[TBL] [Abstract][Full Text] [Related]
15. mTORC1 Inhibition Induces Resistance to Methotrexate and 6-Mercaptopurine in Ph
Vo TT; Lee JS; Nguyen D; Lui B; Pandori W; Khaw A; Mallya S; Lu M; Müschen M; Konopleva M; Fruman DA
Mol Cancer Ther; 2017 Sep; 16(9):1942-1953. PubMed ID: 28566433
[TBL] [Abstract][Full Text] [Related]
16. Curcumin potentiates the anti-leukemia effects of imatinib by downregulation of the AKT/mTOR pathway and BCR/ABL gene expression in Ph+ acute lymphoblastic leukemia.
Guo Y; Li Y; Shan Q; He G; Lin J; Gong Y
Int J Biochem Cell Biol; 2015 Aug; 65():1-11. PubMed ID: 25979368
[TBL] [Abstract][Full Text] [Related]
17. Propofol enhances BCR-ABL TKIs' inhibitory effects in chronic myeloid leukemia through Akt/mTOR suppression.
Tan Z; Peng A; Xu J; Ouyang M
BMC Anesthesiol; 2017 Sep; 17(1):132. PubMed ID: 28962554
[TBL] [Abstract][Full Text] [Related]
18. BCR-ABL1-like acute lymphoblastic leukaemia: From bench to bedside.
Boer JM; den Boer ML
Eur J Cancer; 2017 Sep; 82():203-218. PubMed ID: 28709134
[TBL] [Abstract][Full Text] [Related]
19. Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors.
Pietarinen PO; Eide CA; Ayuda-Durán P; Potdar S; Kuusanmäki H; Andersson EI; Mpindi JP; Pemovska T; Kontro M; Heckman CA; Kallioniemi O; Wennerberg K; Hjorth-Hansen H; Druker BJ; Enserink JM; Tyner JW; Mustjoki S; Porkka K
Oncotarget; 2017 Apr; 8(14):22606-22615. PubMed ID: 28186983
[TBL] [Abstract][Full Text] [Related]
20. The clonal evolution of two distinct T315I-positive BCR-ABL1 subclones in a Philadelphia-positive acute lymphoblastic leukemia failing multiple lines of therapy: a case report.
De Benedittis C; Papayannidis C; Venturi C; Abbenante MC; Paolini S; Parisi S; Sartor C; Cavo M; Martinelli G; Soverini S
BMC Cancer; 2017 Aug; 17(1):523. PubMed ID: 28779753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
